OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions
Stefan Schreiber, Peter M. Irving, Ala I. Sharara, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 6, pp. 658-669
Open Access | Times Cited: 12
Stefan Schreiber, Peter M. Irving, Ala I. Sharara, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 6, pp. 658-669
Open Access | Times Cited: 12
Showing 12 citing articles:
Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis
Tarun Chhibba, Alexandra Frolkis, Lance L. Stein, et al.
Inflammatory Bowel Diseases (2025)
Closed Access | Times Cited: 1
Tarun Chhibba, Alexandra Frolkis, Lance L. Stein, et al.
Inflammatory Bowel Diseases (2025)
Closed Access | Times Cited: 1
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions
Mathieu Uzzan, Yoram Bouhnik, María T. Abreu, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 7, pp. 1066-1078
Closed Access | Times Cited: 24
Mathieu Uzzan, Yoram Bouhnik, María T. Abreu, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 7, pp. 1066-1078
Closed Access | Times Cited: 24
Using data to enable growth of research capability and capacity: a retrospective longitudinal analysis of gastroenterology and hepatology research participation across secondary and tertiary healthcare settings within England
Aditi Kumar, Mohammad Farhad Peerally, Aamir Saifuddin, et al.
Frontline Gastroenterology (2025), pp. flgastro-103038
Closed Access
Aditi Kumar, Mohammad Farhad Peerally, Aamir Saifuddin, et al.
Frontline Gastroenterology (2025), pp. flgastro-103038
Closed Access
Crossing barriers: the burden of inflammatory bowel disease across Western Europe
Aditi Kumar, Nuha Yassin, A Marley, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 9
Aditi Kumar, Nuha Yassin, A Marley, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 9
Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity
Hauke Christian Tews, Tanja Elger, Stefan Gunawan, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Hauke Christian Tews, Tanja Elger, Stefan Gunawan, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD
Sophie Vieujean, James O. Lindsay, Ferdinando D’Amico, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 548-559
Closed Access | Times Cited: 6
Sophie Vieujean, James O. Lindsay, Ferdinando D’Amico, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 548-559
Closed Access | Times Cited: 6
Review article: Externally derived control arms—An opportunity for clinical trials in inflammatory bowel disease?
Sailish Honap, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 7, pp. 659-667
Open Access | Times Cited: 5
Sailish Honap, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 7, pp. 659-667
Open Access | Times Cited: 5
Promising phase II biologics for future Crohn’s disease therapy
Pauline Wils, Silvio Danese, Laurent Peyrin‐Biroulet
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 495-507
Closed Access | Times Cited: 4
Pauline Wils, Silvio Danese, Laurent Peyrin‐Biroulet
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 495-507
Closed Access | Times Cited: 4
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis
An Outtier, Rosanne Janssens, Liese Barbier, et al.
United European Gastroenterology Journal (2024)
Open Access
An Outtier, Rosanne Janssens, Liese Barbier, et al.
United European Gastroenterology Journal (2024)
Open Access
Leveraging Virtual Technology to Conduct Clinical Trials in Inflammatory Bowel Disease.
Nurulamin M Noor, Corey A. Siegel
PubMed (2023) Vol. 19, Iss. 8, pp. 468-474
Closed Access | Times Cited: 1
Nurulamin M Noor, Corey A. Siegel
PubMed (2023) Vol. 19, Iss. 8, pp. 468-474
Closed Access | Times Cited: 1
Partially randomised, patient preference trials for inflammatory bowel disease
Nurulamin M Noor, Corey A. Siegel
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 11, pp. 981-983
Closed Access | Times Cited: 1
Nurulamin M Noor, Corey A. Siegel
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 11, pp. 981-983
Closed Access | Times Cited: 1
Surfing the web as a patient with IBD: New horizons
Iago Rodríguez‐Lago, Ignacio Catalán-Serra, Manuel Barreiro–de Acosta
United European Gastroenterology Journal (2023) Vol. 11, Iss. 7, pp. 592-594
Open Access
Iago Rodríguez‐Lago, Ignacio Catalán-Serra, Manuel Barreiro–de Acosta
United European Gastroenterology Journal (2023) Vol. 11, Iss. 7, pp. 592-594
Open Access
